TY - JOUR
T1 - Toward a roadmap in global biobanking for health
AU - Harris, Jennifer R.
AU - Burton, Paul
AU - Knoppers, Bartha Maria
AU - Lindpaintner, Klaus
AU - Bledsoe, Marianna
AU - Brookes, Anthony J.
AU - Budin-Ljosne, Isabelle
AU - Chisholm, Rex
AU - Cox, David
AU - Deschênes, Mylène
AU - Fortier, Isabel
AU - Hainaut, Pierre
AU - Hewitt, Robert
AU - Kaye, Jane
AU - Litton, Jan Eric
AU - Metspalu, Andres
AU - Ollier, Bill
AU - Palmer, Lyle J.
AU - Palotie, Aarno
AU - Pasterk, Markus
AU - Perola, Markus
AU - Riegman, Peter H J
AU - Van Ommen, Gert Jan
AU - Yuille, Martin
AU - Zatloukal, Kurt
PY - 2012/11
Y1 - 2012/11
N2 - Biobanks can have a pivotal role in elucidating disease etiology, translation, and advancing public health. However, meeting these challenges hinges on a critical shift in the way science is conducted and requires biobank harmonization. There is growing recognition that a common strategy is imperative to develop biobanking globally and effectively. To help guide this strategy, we articulate key principles, goals, and priorities underpinning a roadmap for global biobanking to accelerate health science, patient care, and public health. The need to manage and share very large amounts of data has driven innovations on many fronts. Although technological solutions are allowing biobanks to reach new levels of integration, increasingly powerful data-collection tools, analytical techniques, and the results they generate raise new ethical and legal issues and challenges, necessitating a reconsideration of previous policies, practices, and ethical norms. These manifold advances and the investments that support them are also fueling opportunities for biobanks to ultimately become integral parts of health-care systems in many countries. International harmonization to increase interoperability and sustainability are two strategic priorities for biobanking. Tackling these issues requires an environment favorably inclined toward scientific funding and equipped to address socio-ethical challenges. Cooperation and collaboration must extend beyond systems to enable the exchange of data and samples to strategic alliances between many organizations, including governmental bodies, funding agencies, public and private science enterprises, and other stakeholders, including patients. A common vision is required and we articulate the essential basis of such a vision herein. © 2012 Macmillan Publishers Limited. All rights reserved.
AB - Biobanks can have a pivotal role in elucidating disease etiology, translation, and advancing public health. However, meeting these challenges hinges on a critical shift in the way science is conducted and requires biobank harmonization. There is growing recognition that a common strategy is imperative to develop biobanking globally and effectively. To help guide this strategy, we articulate key principles, goals, and priorities underpinning a roadmap for global biobanking to accelerate health science, patient care, and public health. The need to manage and share very large amounts of data has driven innovations on many fronts. Although technological solutions are allowing biobanks to reach new levels of integration, increasingly powerful data-collection tools, analytical techniques, and the results they generate raise new ethical and legal issues and challenges, necessitating a reconsideration of previous policies, practices, and ethical norms. These manifold advances and the investments that support them are also fueling opportunities for biobanks to ultimately become integral parts of health-care systems in many countries. International harmonization to increase interoperability and sustainability are two strategic priorities for biobanking. Tackling these issues requires an environment favorably inclined toward scientific funding and equipped to address socio-ethical challenges. Cooperation and collaboration must extend beyond systems to enable the exchange of data and samples to strategic alliances between many organizations, including governmental bodies, funding agencies, public and private science enterprises, and other stakeholders, including patients. A common vision is required and we articulate the essential basis of such a vision herein. © 2012 Macmillan Publishers Limited. All rights reserved.
U2 - 10.1038/ejhg.2012.96
DO - 10.1038/ejhg.2012.96
M3 - Article
SN - 1476-5438
VL - 20
SP - 1105
EP - 1111
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 11
ER -